Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock high-impact protein targets long-considered undruggable. The company has developed a new class of stabilized, cell-penetrant alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that are inaccessible to traditional drug modalities. Headquartered in Cambridge, Mass., Parabilis is advancing a focused pipeline of multiple first-in-class therapies across both rare and common cancers. Its lead candidate, FOG-001, is the first direct inhibitor of the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors, implicated in colorectal cancer, desmoid tumors, and a range of other Wnt/β-catenin-driven tumors. Parabilis is also advancing investigational degraders of ERG and ARON for the treatment of prostate cancer, as well as other preclinical programs. What’s the opportunity? The Director, Drug Safety Operations/Pharmacovigilance (PV) will lead and oversee safety reporting activities across clinical programs, with a primary focus on managing and coordinating pharmacovigilance deliverables with Contract Research Organizations (CROs) and consultants. This role ensures compliance with global regulatory requirements, company SOPs, and high-quality execution of safety reporting obligations. This position will act as the key liaison between internal stakeholders and CRO partners and consultants to drive operational excellence and regulatory compliance in pharmacovigilance activities. The successful candidate will report to the VP of Clinical Safety and Pharmacovigilance.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director